Gilead Revenue Per Employee vs Net Income Per Employee Analysis
GILD Stock | USD 67.03 0.08 0.12% |
Trend analysis of Gilead Sciences balance sheet accounts such as Other Current Liabilities of 11.8 B or Total Current Liabilities of 11.8 B provides information on Gilead Sciences' total assets, liabilities, and equity, which is the actual value of Gilead Sciences to its prevalent stockholders. By breaking down trends over time using Gilead Sciences balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Gilead |
About Gilead Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Gilead Sciences at a specified time, usually calculated after every quarter, six months, or one year. Gilead Sciences Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Gilead Sciences and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Gilead currently owns. An asset can also be divided into two categories, current and non-current.
Gilead Sciences Balance Sheet Chart
Gilead Sciences Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Gilead Sciences uses and utilizes its capital. It also shows what exactly a company owns and owes.
At present, Gilead Sciences' Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 11.8 B, whereas Cash is forecasted to decline to about 3.8 B. Add Fundamental
Total Assets
Total assets refers to the total amount of Gilead Sciences assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Gilead Sciences books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Gilead Sciences balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Gilead Sciences are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from Gilead Sciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Gilead Sciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.At present, Gilead Sciences' Tax Provision is projected to decrease significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 0.30, whereas Issuance Of Capital Stock is forecasted to decline to about 295.9 M.
2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 27.3B | 27.3B | 27.1B | 28.5B | Interest Expense | 1.0B | 935M | 944M | 534.5M |
Gilead Sciences fundamental ratios Correlations
Click cells to compare fundamentals
Gilead Sciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Gilead Sciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 61.6B | 68.4B | 68.0B | 63.2B | 62.1B | 65.2B | |
Short Long Term Debt Total | 24.6B | 31.4B | 26.7B | 25.2B | 25.0B | 26.2B | |
Other Current Liab | 6.5B | 7.8B | 9.4B | 8.1B | 11.3B | 11.8B | |
Total Current Liabilities | 9.8B | 11.4B | 11.6B | 11.2B | 11.3B | 11.8B | |
Total Stockholder Equity | 22.7B | 18.2B | 21.1B | 21.2B | 22.7B | 23.9B | |
Property Plant And Equipment Net | 4.5B | 5.0B | 5.1B | 5.5B | 5.3B | 5.6B | |
Net Debt | 13.0B | 25.4B | 21.4B | 19.8B | 18.9B | 19.8B | |
Retained Earnings | 19.4B | 14.4B | 16.3B | 15.7B | 16.3B | 17.1B | |
Accounts Payable | 713M | 844M | 705M | 905M | 550M | 518.2M | |
Cash | 11.6B | 6.0B | 5.3B | 5.4B | 6.1B | 3.8B | |
Non Current Assets Total | 30.1B | 52.6B | 52.9B | 47.9B | 45.7B | 48.0B | |
Non Currrent Assets Other | 7.7B | 6.4B | 6.0B | 4.0B | 5.6B | 5.9B | |
Cash And Short Term Investments | 25.8B | 7.9B | 7.8B | 7.6B | 8.4B | 7.5B | |
Common Stock Shares Outstanding | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.5B | |
Liabilities And Stockholders Equity | 61.6B | 68.4B | 68.0B | 63.2B | 62.1B | 65.2B | |
Non Current Liabilities Total | 29.2B | 38.8B | 35.3B | 30.7B | 28.1B | 29.5B | |
Other Current Assets | 1.4B | 2.0B | 2.1B | 1.8B | 2.4B | 1.3B | |
Other Stockholder Equity | 3.2B | 3.9B | 4.7B | 5.5B | (16.3B) | (15.5B) | |
Total Liab | 39.0B | 50.2B | 46.9B | 42.0B | 39.4B | 41.3B | |
Total Current Assets | 31.5B | 15.8B | 15.1B | 15.2B | 16.5B | 10.8B | |
Short Term Debt | 2.5B | 2.8B | 1.5B | 2.3B | 1.8B | 1.9B | |
Net Receivables | 3.6B | 4.9B | 4.5B | 4.8B | 4.7B | 2.4B | |
Property Plant And Equipment Gross | 4.5B | 5.0B | 7.0B | 7.7B | 7.8B | 8.2B | |
Accumulated Other Comprehensive Income | 85M | (60M) | 83M | 2M | 28M | 37.6M | |
Short Term Investments | 12.7B | 1.4B | 1.2B | 973M | 1.2B | 1.1B | |
Inventory | 2.1B | 3.0B | 2.7B | 2.8B | 3.4B | 3.5B | |
Other Liab | 6.5B | 9.5B | 35.3B | 7.3B | 8.4B | 8.8B | |
Other Assets | 3.1B | 4.8B | 6.0B | 1M | 1.2M | 1.1M | |
Long Term Debt | 22.1B | 28.6B | 25.2B | 23.0B | 23.2B | 12.2B | |
Property Plant Equipment | 4.5B | 5.0B | 5.1B | 5.5B | 6.3B | 6.6B | |
Net Tangible Assets | 4.6B | (23.0B) | (20.7B) | (16.0B) | (14.4B) | (13.7B) | |
Noncontrolling Interest In Consolidated Entity | 125M | 19M | (5M) | (31M) | (84M) | (79.8M) | |
Retained Earnings Total Equity | 19.4B | 14.4B | 16.3B | 15.7B | 18.0B | 12.7B | |
Long Term Debt Total | 22.1B | 28.6B | 25.2B | 23.0B | 26.4B | 19.7B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for Gilead Stock analysis
When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Transaction History View history of all your transactions and understand their impact on performance | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Money Managers Screen money managers from public funds and ETFs managed around the world |
Is Gilead Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Dividend Share 3 | Earnings Share 4.5 | Revenue Per Share 21.728 | Quarterly Revenue Growth (0.04) |
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.